ENDRA Life Sciences (NDRA) Cash from Operations (2016 - 2026)

ENDRA Life Sciences has disclosed Cash from Operations across 11 years of filings, most recently posting 1119650.0 for Q1 2026.

• In Q1 2026, Cash from Operations rose 13.42% year-over-year to 1119650.0; the TTM figure through Mar 2026 stood at 5009079.0 (up 23.52% YoY), while the FY2025 annual figure was 5182558.0, up 29.97% from the prior year.
• Cash from Operations climbed to 1119650.0 in Q1 2026, from 1611711.0 in the prior quarter.
• Over the last five years, Cash from Operations for NDRA reached as high as 1113715.0 in Q2 2025 and fell as low as 3334982.0 in Q2 2022.
• The 5-year median for Cash from Operations is 2144312.0 (2024), against an average of 2118876.53.
• Annual changes were most pronounced in 2022 — Cash from Operations slipped 19.13% — and 2025, when it jumped 46.54%.
• A 5-year view of Cash from Operations shows it stood at 3088689.0 in 2022, then gained by 29.6% to 2174578.0 in 2023, then soared by 30.3% to 1515705.0 in 2024, then retreated by 6.33% to 1611711.0 in 2025, then jumped by 30.53% to 1119650.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 1119650.0, 1611711.0, and 1164003.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.